BioSpace News Archive

Molecular diagnostics company Genetic Technologies Limited is pleased to announce the issuance of US Patent No: US 10,683,549, Methods for assessing risk of developing breast cancer.

Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Company management, including Mike Sherman, Chief Executive Officer, and Mike Andriole, Chief Business and Financial Officer, will participate in a fireside chat at the H.C. Wainwright Virtual Fireside Chat Series on Thursday, June 25, 2020 at 12:05 p.m. ET.

--Companies will leverage their highly complementary technologies to address target specificity for tumor cells and cell exhaustion, two significant barriers for solid tumor T cell therapy--

Tempest, an integrated, evidence-based digital recovery program, is launching an expanded membership model to revolutionize the care model for individuals on the spectrum of Alcohol Use Disorder.

Teva Presents New Analyses Examining Changes in Migraine Disability Outcome Measurements with AJOVY ® (fremanezumab-vfrm) Injection Open-label extension of the FOCUS Phase IIIb study examined changes in quality of life, health status, depressive symptoms and work productivity over 12 weeks Pooled Phase 3 results examined changes in disability using American Headache Society guidelines TEL AVIV & PARSIPPANY, N.J.--( BUSINESS WIRE )-- Tev

MedX Health Corp. (“MedX”) ( MDX – TSXV), announced today that President and CEO Scott Spearn has resigned for family reasons, effective immediately. Rob von der Porten, Chairman of the Board, has been named interim Executive Chair. Mr. Spearn will also be retiring from the Board at or prior to the next AGM. The Board will commence a search for suitable candidates to take on the CEO position. “The Board than

Nimbus Therapeutics , a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, will host a webcast seminar to discuss the latest data from its HPK1 program on Thursday, June 25, from 11 a.m. to 12 p.m. ET. The seminar will feature presentations by Nimbus’ scientific leadership that give a brief overview of the company’s discovery pipeline and a deeper dive on

Lineage Cell Therapeutics Reinitiates Patient Enrollment in Clinical Study of OpRegen ® for the Treatment of Dry AMD With Geographic Atrophy First OpRegen Patient Dosed at Cincinnati Eye Institute CARLSBAD, Calif.--( BUSINESS WIRE )-- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage cell therapy company which manufactures and transplants specific cell types to treat diseases and serious medical conditions, today anno

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced dosing of the first patient in a phase 1 clinical trial evaluating investigational agent SEA-TGT, also known as SGN-TGT, an anti-TIGIT antibody for patients with solid tumors and

Partnership Aims to Answer Key Questions in Multiple Myeloma Patient Care and Accelerate Discovery and Development of New Treatments